This study aims to evaluate efficacy and tolerance of real life neoadjuvant immunotherapy in advanced yet operable melanoma.
The complete histological response will be assessed.
Patients with operable metastatic melanoma (stage III or IV of American Joint Committee on Cancer [AJCC] Stages CLassification) treated with neoadjuvant immunotherapy (anti-PD1 or anti-PD1 + anti-CTLA-4), even if surgery cancelled due to disease progression or complete response or patient's refusal to be operated.
Efficacy of the neoadjuvant immunotherapy histologically of radiologically assessed
Uveal melanoma
Patients with operable metastatic melanoma (stade III or IV of AJCC) treated with neoadjuvant immunotherapy (anti-PD1 or anti-PD1 + anti-CTLA-4)
Case-only
Retrospective
Not listed
Complete histological response
Histological response rate on histological analysis of the resected specimen
Objectival response rate
Objectival response rate on imaging
Event-free survival
An event is defined by progression of the disease or toxicity making surgery impossible, the impossibility of starting adjuvant treatment within 84 days following surgery, recurrence of melanoma after surgery or death.
Disease Free Survival after surgery
Overall survival
Click on the lead sponsor to view all of their trials.
